Outcome Measures Used in Ocular Gene Therapy Trials: A Scoping Review of Current Practice

Overview

Journal Front Pharmacol

Date 2019 Oct 18

PMID 31620003

Citations 15

Authors

Jasleen K Jolly

Holly Bridge

Robert E MacLaren

Affiliations

Soon will be listed here.

Abstract

Multiple gene therapy trials are occurring for a variety of ophthalmic diseases around the world. The safety of gene therapy in the eye has been established, and the next step is to reliably assess efficacy. This is primarily done through the use of imaging techniques and visual function measures. Standardized visual function assessments, however, were originally developed for a clinical setting and may not be suitable for detecting and quantifying therapeutic changes. This scoping review takes a comprehensive look at current practice in terms of the outcome measures defined at trial registration. These were compared to the outcome measures reported in the literature. All published trials reported the pre-registered primary outcome measure. A range of additional secondary outcomes were reported that were not originally planned. Gaps in gene therapy assessment exist and further discussion are required to find a way forward, particularly as more conditions progress to phase 2 and 3 trials. Several factors impacting on trial design and outcome measure choice are discussed.

Citing Articles

Neurochemistry and functional connectivity in the brain of people with Charles Bonnet syndrome.

Bridge H, Wyllie A, Kay A, Rand B, Starling L, Millington-Truby R Ther Adv Ophthalmol. 2024; 16:25158414241280201.

PMID: 39416975 PMC: 11481065. DOI: 10.1177/25158414241280201.

Optical Coherence Tomography Split-Spectrum Amplitude-Decorrelation Optoretinography Detects Early Central Cone Photoreceptor Dysfunction in Retinal Dystrophies.

Wongchaisuwat N, Amato A, Yang P, Everett L, Pennesi M, Huang D Transl Vis Sci Technol. 2024; 13(10):5.

PMID: 39361318 PMC: 11451826. DOI: 10.1167/tvst.13.10.5.

ISCEV and IPS guideline for the full-field stimulus test (FST).

Jolly J, Grigg J, McKendrick A, Fujinami K, Cideciyan A, Thompson D Doc Ophthalmol. 2024; 148(1):3-14.

PMID: 38238632 PMC: 10879267. DOI: 10.1007/s10633-023-09962-7.

Choroideremia: The Endpoint Endgame.

Abdalla Elsayed M, Taylor L, Josan A, Fischer M, MacLaren R Int J Mol Sci. 2023; 24(18).

PMID: 37762657 PMC: 10532430. DOI: 10.3390/ijms241814354.

A cross-sectional study to assess the clinical utility of modern visual function assessments in patients with inherited retinal disease: a mixed methods observational study protocol.

Taylor L, Josan A, Stratton I, Jolly J, MacLaren R BMC Ophthalmol. 2023; 23(1):234.

PMID: 37226218 PMC: 10210467. DOI: 10.1186/s12886-023-02974-6.

References

Constable I, Lai C, Magno A, French M, Barone S, Schwartz S . Gene Therapy in Neovascular Age-related Macular Degeneration: Three-Year Follow-up of a Phase 1 Randomized Dose Escalation Trial. Am J Ophthalmol. 2017; 177:150-158. DOI: 10.1016/j.ajo.2017.02.018. View

Bennett J, Wellman J, Marshall K, McCague S, Ashtari M, DiStefano-Pappas J . Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial. Lancet. 2016; 388(10045):661-72. PMC: 5351775. DOI: 10.1016/S0140-6736(16)30371-3. View

Maguire A, High K, Auricchio A, Wright J, Pierce E, Testa F . Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. Lancet. 2009; 374(9701):1597-605. PMC: 4492302. DOI: 10.1016/S0140-6736(09)61836-5. View

Le Meur G, Lebranchu P, Billaud F, Adjali O, Schmitt S, Bezieau S . Safety and Long-Term Efficacy of AAV4 Gene Therapy in Patients with RPE65 Leber Congenital Amaurosis. Mol Ther. 2017; 26(1):256-268. PMC: 5763029. DOI: 10.1016/j.ymthe.2017.09.014. View

Lam B, Davis J, Gregori N, MacLaren R, Girach A, Verriotto J . Choroideremia Gene Therapy Phase 2 Clinical Trial: 24-Month Results. Am J Ophthalmol. 2018; 197:65-73. DOI: 10.1016/j.ajo.2018.09.012. View

Cideciyan A, Aguirre G, Jacobson S, Butt O, Schwartz S, Swider M . Pseudo-fovea formation after gene therapy for RPE65-LCA. Invest Ophthalmol Vis Sci. 2014; 56(1):526-37. PMC: 4303042. DOI: 10.1167/iovs.14-15895. View

Bainbridge J, Mehat M, Sundaram V, Robbie S, Barker S, Ripamonti C . Long-term effect of gene therapy on Leber's congenital amaurosis. N Engl J Med. 2015; 372(20):1887-97. PMC: 4497809. DOI: 10.1056/NEJMoa1414221. View

Weleber R, Pennesi M, Wilson D, Kaushal S, Erker L, Jensen L . Results at 2 Years after Gene Therapy for RPE65-Deficient Leber Congenital Amaurosis and Severe Early-Childhood-Onset Retinal Dystrophy. Ophthalmology. 2016; 123(7):1606-20. DOI: 10.1016/j.ophtha.2016.03.003. View

Patricio M, Barnard A, Orlans H, McClements M, MacLaren R . Inclusion of the Woodchuck Hepatitis Virus Posttranscriptional Regulatory Element Enhances AAV2-Driven Transduction of Mouse and Human Retina. Mol Ther Nucleic Acids. 2017; 6:198-208. PMC: 5363497. DOI: 10.1016/j.omtn.2016.12.006. View

10.

Cideciyan A, Hauswirth W, Aleman T, Kaushal S, Schwartz S, Boye S . Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 year. Hum Gene Ther. 2009; 20(9):999-1004. PMC: 2829287. DOI: 10.1089/hum.2009.086. View

11.

Salvetti A, Patricio M, Barnard A, Orlans H, Hickey D, MacLaren R . Impact of Vital Dyes on Cell Viability and Transduction Efficiency of AAV Vectors Used in Retinal Gene Therapy Surgery: An In Vitro and In Vivo Analysis. Transl Vis Sci Technol. 2017; 6(4):4. PMC: 5505121. DOI: 10.1167/tvst.6.4.4. View

12.

Jolly J, Xue K, Edwards T, Groppe M, MacLaren R . Characterizing the Natural History of Visual Function in Choroideremia Using Microperimetry and Multimodal Retinal Imaging. Invest Ophthalmol Vis Sci. 2017; 58(12):5575-5583. PMC: 5850987. DOI: 10.1167/iovs.17-22486. View

13.

Hauswirth W, Aleman T, Kaushal S, Cideciyan A, Schwartz S, Wang L . Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum Gene Ther. 2008; 19(10):979-90. PMC: 2940541. DOI: 10.1089/hum.2008.107. View

14.

Cideciyan A, Aleman T, Boye S, Schwartz S, Kaushal S, Roman A . Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Proc Natl Acad Sci U S A. 2008; 105(39):15112-7. PMC: 2567501. DOI: 10.1073/pnas.0807027105. View

15.

Koilkonda R, Yu H, Chou T, Feuer W, Ruggeri M, Porciatti V . Safety and effects of the vector for the Leber hereditary optic neuropathy gene therapy clinical trial. JAMA Ophthalmol. 2014; 132(4):409-20. PMC: 4266107. DOI: 10.1001/jamaophthalmol.2013.7630. View

16.

Jolly J, Edwards T, Moules J, Groppe M, Downes S, MacLaren R . A Qualitative and Quantitative Assessment of Fundus Autofluorescence Patterns in Patients With Choroideremia. Invest Ophthalmol Vis Sci. 2016; 57(10):4498-4503. PMC: 5860725. DOI: 10.1167/iovs.15-18362. View

17.

Ghazi N, Abboud E, Nowilaty S, Alkuraya H, Alhommadi A, Cai H . Treatment of retinitis pigmentosa due to MERTK mutations by ocular subretinal injection of adeno-associated virus gene vector: results of a phase I trial. Hum Genet. 2016; 135(3):327-43. DOI: 10.1007/s00439-016-1637-y. View

18.

Wan X, Pei H, Zhao M, Yang S, Hu W, He H . Efficacy and Safety of rAAV2-ND4 Treatment for Leber's Hereditary Optic Neuropathy. Sci Rep. 2016; 6:21587. PMC: 4759604. DOI: 10.1038/srep21587. View

19.

Xue K, Groppe M, Salvetti A, MacLaren R . Technique of retinal gene therapy: delivery of viral vector into the subretinal space. Eye (Lond). 2017; 31(9):1308-1316. PMC: 5601444. DOI: 10.1038/eye.2017.158. View

20.

Fischer M, Ochakovski G, Beier B, Seitz I, Vaheb Y, Kortuem C . CHANGES IN RETINAL SENSITIVITY AFTER GENE THERAPY IN CHOROIDEREMIA. Retina. 2018; 40(1):160-168. DOI: 10.1097/IAE.0000000000002360. View